We have demonstrated pre-clinically and more recently clinically, that by combining Ipilimumab (an anti-CTLA4 antibody) , a currently approved treatment for metastatic melanoma, with our intratumoral IMO-2125, we can enable these therapies to have deeper and longer-lasting responses in patients who are refractory to anti-PD1 therapy.
Along with our research alliance partner, MD Anderson Cancer Center, we have recently completed enrollment in the dose escalation phase of our clinical trial of IMO-2125 in combination with Ipilimumab in PD-1 refractory metastatic melanoma patients. We’ll soon be selecting our dose and advancing to the Phase 2 portion of the trial which will enroll 21 patients at the selected dose. We also are enrolling an arm in the trial to test the combination of IMO-2125 with Pemrolizumab and have plans to begin additional studies during 2017 to study IMO-2125 as a monotherapy and explore additional combination regimens and other tumor types. For more information on this study, go to the U.S. FDA Clinical Trial Registry Website ,contact Idera at firstname.lastname@example.org or visit Idera’s Clinical Trials Website.